HistoRx has appointed Paul Stroobant vice president and head of research. Stroobant most recently served BG Medicine as vice president of biochemistry and protein discovery. Prior to that position, he was chief scientific officer of Differential Proteomics, he held a series of research management positions at Millennium Pharmaceuticals, including director of proteomics of Millennium Predictive Medicine, and served as director of biochemistry at Cell Genesys. Stroobant holds a PhD in biochemistry from the Australian National University.
Deborah Dunsire will be the new president and CEO of Millennium Pharmaceuticals on August 1. She is currently head of Novartis Pharmaceuticals' North American oncology operations. Dunsire will also assume a position on Millennium's board of directors. Dunsire succeeds Mark Levin, who served Millennium as co-founder and CEO since its inception. Millennium board member Kenneth Weg will become the new non-executive chairman. Levin will remain on the board.
Thomas Hudson has been named to the scientific advisory board of Biopotential Capital, the Calgary, Alberta-based venture capital firm said June 14.
Hudson is an associate professor and associate physician in the departments of medicine & human genetics at McGill University and is the founder and director of the McGill University and Genome Quebec Innovation Centre. He is also the editor-in-chief of the journal Human Genetics.
Hudson formerly served as assistant director of the Whitehead Institute/MIT Center for Genome Research and chaired the Science Committee of Genome Canada.
Illumina said last week that it had begun shipping its Sentrix Human-1 Genotyping BeadChip. The new BeadChip can interrogate "more than 100,000" SNP loci per sample, with "more than 70 percent" of those markers located in or near genes, the company said in a statement. The company's Infinium genotyping protocol, along with the new BeadChip results in call rates of 99.4 percent, reproducibility of 99.99 percent, and accuracy of 99.99 percent, as measured by Mendelian consistencies, the company said.
Affymetrix has released its GeneChip Scanner 3000 7G, an upgraded version of its GCS 3000, which can be configured as part of the GCS 3000 MegAllele System, and supports multiplexed assays for custom genotyping developed using ParAllele Bioscience's molecular inversion probe technology. According to Affymetrix, the new scanner supports four-color scanning for use in MegAllele assays, fits into a benchtop environment, uses a solid state laser, and supports newer high-density Affymetrix GeneChip microarrays for tiling, all-exon, and SNP genotyping research. The scanner also includes a dual processor workstation and software updates for processing and analyzing the data generated per experiment. Users can either purchase the new system or request an upgrade to include the new scanner, Affy said.